Does testosterone replacement therapy benefit healthy older men?
Moderate EvidenceIT DEPENDS
Moderate evidence shows testosterone replacement in older men with low levels modestly improves sexual function, mood, and bone density, but cardiovascular safety remains uncertain and benefits are smaller than commonly claimed.
The Verdict
Moderate evidence shows testosterone replacement in older men with low levels modestly improves sexual function, mood, and bone density, but cardiovascular safety remains uncertain and benefits are smaller than commonly claimed.
What the Evidence Shows
The Testosterone Trials (TTrials), a coordinated set of seven RCTs in 790 men aged 65+ with low testosterone, demonstrated modest improvements in sexual function, physical activity, and vitality after 12 months of treatment. A 2018 systematic review confirmed benefits for sexual function and body composition but found inconsistent effects on cognitive function and physical performance. However, the cardiovascular safety profile remains concerning. The TOM trial was stopped early due to increased cardiovascular adverse events in frail elderly men receiving testosterone. A JAMA analysis from the TTrials found increased coronary artery plaque volume in the testosterone group. The risk-benefit balance appears most favorable for men with clearly symptomatic hypogonadism and least favorable for men seeking anti-aging benefits with borderline-low levels.
Evidence Quality
3
Meta-Analyses
12
RCTs
15
Observational
Important Caveats
- ⚠️ Benefits are most clearly demonstrated for sexual function, not overall vitality
- ⚠️ Cardiovascular safety is not fully established—some trials show increased plaque burden
- ⚠️ The TOM trial was stopped early due to adverse cardiovascular events in frail men
- ⚠️ Most trials lasted only 12 months—long-term outcomes remain unclear
- ⚠️ Benefits diminish in men with testosterone levels only mildly below normal
- ⚠️ Prostate safety with long-term use requires further study
Population Studied
Men aged 65 and older with serum testosterone below 275 ng/dL; primarily community-dwelling with age-related decline
Dosage
Transdermal testosterone gel (AndroGel 1%) titrated to achieve mid-normal testosterone levels (400-700 ng/dL)
Duration
Most RCTs lasted 6-12 months; no long-term (>3 year) outcome trials completed
Supporting Studies (3)
Effects of Testosterone Treatment in Older Men
RCTSnyder PJ, Bhasin S, Cunningham GR, et al. · New England Journal of Medicine (2016)
In 790 men aged 65+ with low testosterone, 12 months of testosterone gel modestly improved sexual function, walking distance, and vitality compared to placebo, though effects on physical function were inconsistent.
View paper (DOI) →Testosterone Replacement Therapy in Men: A Systematic Review and Meta-Analysis
Meta-AnalysisBhasin S, Brito JP, Cunningham GR, et al. · Journal of Clinical Endocrinology & Metabolism (2018)
Systematic review of RCTs confirmed testosterone therapy improves sexual function, modestly increases lean mass, reduces fat mass, and improves bone mineral density, but effects on cognition, vitality, and physical function are inconsistent.
View paper (DOI) →Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone
RCTBudoff MJ, Ellenberg SS, Lewis CE, et al. · JAMA (2017)
In the TTrials cardiovascular substudy, testosterone treatment was associated with a significantly greater increase in coronary artery noncalcified plaque volume compared with placebo over 12 months.
View paper (DOI) →Contradicting Studies (1)
Adverse Events Associated with Testosterone Administration
RCTBasaria S, Coviello AD, Travison TG, et al. · New England Journal of Medicine (2010)
The TOM trial in men aged 65+ with mobility limitations was stopped early because the testosterone group experienced significantly more cardiovascular adverse events (heart attacks, strokes, elevated blood pressure) than placebo.
Why this disagrees:
Demonstrates that testosterone replacement may pose serious cardiovascular risks in older, frail men, suggesting the risk-benefit profile is unfavorable for this population. The early termination due to safety concerns directly challenges the notion that testosterone therapy is broadly beneficial for aging men.